Skip to main content
. 2009 Sep 8;27(31):5208–5212. doi: 10.1200/JCO.2009.22.5748

Fig 1.

Fig 1.

Kaplan-Meier survival curves by treatment arm with 5 years of follow-up. (A) Intent-to-treat population (n = 241). (B) Responding patients (ie, patients with a complete or partial response; n = 103). (C) Patients with fludarabine-sensitive disease (n = 101). OBL-FC, oblimersen plus fludarabine/cyclophosphamide; FC, fludarabine/cyclophosphamide.